Nanmo Biotechnology

What Nanmo Biotechnology does

Commercially, Nanmo serves three customer segments: pharmaceutical and biotech companies (including Akeso, Kelun-Biotech, Baili-Tianqing, Summit Therapeutics, BMS, and Merck/MSD), academic and government research institutions (including the Chinese Academy of Sciences), and contract research organizations. Revenue is generated through one-time model license sales (catalog and custom), professional services fees for preclinical CRO studies, and recurring supporting services for breeding, cryopreservation, animal room management, and genotyping. Pricing is quote-based rather than publicly disclosed, and go-to-market is sales-led via direct enterprise accounts, technical hotlines, WeChat consultation, and content marketing through the company website and industry conferences such as ASCO. The company is listed on the Shanghai Stock Exchange STAR Market and serves customers across China, the United States, and the United Kingdom.

Name

Nanmo Biotechnology

Legal name

上海南方模式生物科技股份有限公司

Website

https://modelorg.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Nanmo Biotechnology is a Shanghai-listed life sciences firm that designs and supplies gene-modified animal models (mice, rats, cell lines) and integrated preclinical CRO services to pharmaceutical companies, biotech firms, and academic research institutions across China, the US, and the UK.

Ownership category

akta.pro rank

Product category

Preclinical Research Models and CRO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Genetically modified mice
• Preclinical CRO services
• Humanized mouse models
• Gene knockout models
• Disease mouse models

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Ready-made Model Sales: Sale of catalog genetic modification models including knockout mice, humanized mice, immunodeficient mice, tool mice, and disease models. Over 16,000 ready-made models available.
2. Custom Model Development: Bespoke gene modification model services using SmartEddi® system for gene knockout, knock-in, point mutations, and humanization based on client specifications.
3. Preclinical CRO Services: Contract research services including in vivo/in vitro efficacy testing, toxicology, and pathology services for drug discovery.
4. Supporting Services: Breeding services, cryopreservation, animal room management, and genotyping services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Nanmo Biotechnology develops, breeds, and sells genetically modified laboratory animal models (mice, rats, zebrafish) and cell lines for life science research and preclinical drug discovery. Its portfolio includes 16,000+ catalog ready-made models, custom gene-modified model generation services delivered through its SmartEddi® platform, and integrated preclinical CRO services spanning tumor, metabolic, inflammation/autoimmune, and neurological disease efficacy evaluation. Customers include pharmaceutical and biotech companies, academic research institutions, and CROs in China and internationally.

Product overview

Nanmo Biotechnology (南模生物) is a Shanghai-based biotech company (stock code: 688265) specializing in gene-modified model organisms, offering an integrated portfolio of products and preclinical CRO services. The core offering comprises over 16,000 finished gene-modified animal models (mice, rats, cell lines) and custom model generation services through the SmartEddi intelligent customization system. The preclinical CRO services span tumor efficacy evaluation (syngeneic, CDX, PDX, humanized models), metabolism/cardiovascular disease evaluation, inflammation/autoimmune disease evaluation, neurological disease evaluation, cell line services, in vitro/vivo efficacy testing, and toxicology/pathology services. Supporting services include model breeding, preservation, animal management, and genotyping.

Differentiator

Problem solved

Functional benefit

Brands

• SmartEddi: SmartEddi intelligent mouse model customization system - an intelligent customization system for quickly obtaining mouse model customization solutions
• U-DMbase

Quantifiable outcome

• Supporting research published in top-tier journals including Cell, Nature, Science, and their sub-journals
• +1 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Jackson Laboratory: Global leader in mouse model distribution and genetically defined mouse strains with deep academic and pharma penetration. Competes with Nanmo on catalog model distribution and serves as the international benchmark for quality and IP-rich model libraries.
• WuXi AppTec: China-based global CRO/CDMO with preclinical biology services including animal model studies. Overlaps with Nanmo in preclinical efficacy testing, though much broader in service scope and scale.
• Charles River Laboratories: Global CRO offering preclinical research services including model organism supply and efficacy/safety evaluation. Overlaps with Nanmo's preclinical CRO segment, particularly for multinational pharma clients, though Charles River is far broader in scope.

Regional players

• Inotiv: US-based preclinical CRO with model organism supply and contract research services. Comparable business model combining model supply with preclinical studies, though primarily serving North American customers.
• Pharmaron: China-rooted global CRO offering preclinical services including animal model-based drug efficacy/toxicology evaluation. Comparable in CRO services scope with both Chinese and international footprint.

Direct peers

• Biocytogen: China-based biotech offering humanized mouse models (RenMab/RenLite platforms) and preclinical services. Direct competitor with proprietary humanized antibody platforms and similar pharma/biotech customer profile.
• GemPharmatech: Chinese model organism CRO specializing in gene-modified mouse models and preclinical services. Direct competitor offering similar knockout, knockin, and humanized mouse capabilities, with overlapping customer base in Chinese biotech.
• Cyagen Biosciences: China-based and US-operating provider of custom genetically modified mouse/rat models and cell line services. Direct competitor in custom model generation with similar CRISPR/Cre-Lox technology stack.
• Crown Bioscience (JSR Life Sciences): Preclinical CRO with extensive humanized mouse and oncology model portfolio. Directly comparable in the preclinical efficacy evaluation segment, particularly for oncology and immuno-oncology applications.
• Taconic Biosciences: Specialty provider of genetically engineered mice and rats with strong pharma/biotech customer base. Directly comparable business model focused on catalog and custom model sales, serving similar drug discovery end markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanmo Biotechnology